Merck KGaA May Divest Generics

Merck KGaA is considering plans to divest its generic drugs business and could raise up to €4 billion ($5.3 billion) from the sale, according to a report in German newspaper Handelsblatt on January 4. Merck KGaA declined to comment on the report. Selling generics would cut Merck KGaA’s debt following the company’s imminent purchase of biotechnology firm Serono for over $13 billion. Private equity firms, rather than pharmaceutical manufacturers, are more likely to be interested in buying Merck KGaA’s generics, analysts say. Merck KGaA is one...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers